Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of total gastrectomy on weight and body composition: A retrospective study.

Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition·2026
Same author

Neoadjuvant therapy with an aromatase inhibitor and durvalumab in postmenopausal patients with hormone receptor-positive breast cancer.

Breast cancer research and treatment·2026
Same author

NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Nutritional Support for Gastrointestinal Cancer Patients: New (and Old) Frontiers in Management, a Narrative Review.

Nutrients·2025
Same author

A patient-mediated implementation strategy to improve nutrition care delivery for esophageal and gastric cancer: a study protocol for a pilot randomized controlled trial.

Journal of health, population, and nutrition·2025
Same author

Race-based differences in serum biomarkers for cancer-associated cachexia in a diverse cohort of patients with pancreatic ductal adenocarcinoma.

Communications medicine·2025

Related Experiment Video

Updated: May 30, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Phyllodes tumors: race-related differences.

Jose M Pimiento1, Pranjali V Gadgil, Alfredo A Santillan

  • 1Don & Erika Wallace Comprehensive Breast Program, Department of Women's Oncology, H Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA. jose.pimiento@moffitt.org

Journal of the American College of Surgeons
|August 23, 2011
PubMed
Summary
This summary is machine-generated.

Phyllodes tumors (PT) show racial differences in pathology, with Hispanic patients having more high-grade tumors. These differences did not impact short-term survival outcomes in this study.

More Related Videos

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Related Experiment Videos

Last Updated: May 30, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Area of Science:

  • Oncology
  • Pathology
  • Breast Cancer Research

Background:

  • Phyllodes tumors (PT) are rare breast malignancies with unpredictable behavior and high recurrence rates.
  • Limited data exists regarding racial disparities in PT presentation and outcomes.
  • This study aims to elucidate potential racial differences in PT.

Purpose of the Study:

  • To investigate racial differences in the pathological features of Phyllodes tumors (PT).
  • To determine if observed racial differences in PT pathology correlate with clinical outcomes.
  • To identify factors influencing PT behavior across different racial groups.

Main Methods:

  • Retrospective review of 124 patients diagnosed with PT between 1999 and 2010.
  • Data collected from Moffitt Cancer Center and University of Texas Health Science Center.
  • Analysis of patient demographics, tumor characteristics, and recurrence rates.

Main Results:

  • Hispanic patients (43%) presented with a higher percentage of borderline and malignant PT compared to other races (p < 0.01).
  • Hispanic patients also showed a tendency for larger tumor size and higher mitotic rates (p = 0.01; p = 0.03).
  • Local recurrence (6.4%) was associated with tumor size, grade, mitotic rate, and margin status, but not significantly by race.

Conclusions:

  • Significant pathological differences in PT exist across racial groups, notably higher-grade tumors in Hispanic patients.
  • These pathological variations did not lead to significant differences in survival at short-term follow-up.
  • Further research is needed to explore molecular, geographic, and socioeconomic factors influencing PT.